Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSV 1716

Drug Profile

HSV 1716

Alternative Names: Herpes simplex virus 1716 - Virttu; HSV1716; Oncolytic HSV-1716; Seprehvir

Latest Information Update: 29 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crusade Laboratories
  • Developer Nationwide Children's Hospital; Pediatric Brain Tumor Consortium; Virttu Biologics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Solid tumours
  • Preclinical Prostate cancer
  • No development reported Glioblastoma; Glioma; Malignant melanoma; Squamous cell cancer

Most Recent Events

  • 29 Mar 2018 HSV 1716 is still in phase I trials for Solid Tumours (Second line therapy or greater, In adolescent, In adults, In children) in USA (Intratumoural; IV) (NCT00931931)
  • 19 Mar 2018 Nationwide Children's Hospital completes a phase I trial in Solid Tumours (Second line therapy or greater, In adolescent, In adults, In children) in USA (Intratumoural; IV) (NCT00931931)
  • 05 Mar 2018 Sorrento Therapeutics plans a clinical trial for Cancer (Combination therapy) in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top